INFO & CONTACTS:  +39 02 2390 1

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

Phase: Phase II clinical trials

Principal Investigator: Dott. Duca Matteo

Main Facility: Oncologia Medica 1

Drug: BMS-986504

Pathologies: Advanced Solid Tumours, Melanoma, Pancreatic cancer, Lung cancer

ClinicalTrials.gov: Read the details

Phase II study evaluating the efficacy and safety of BMS-986504, a next-generation PRMT5 inhibitor, as monotherapy or in combination with other anticancer agents, in patients with advanced and/or metastatic solid tumors characterized by MTAP deletion. The study also aims to identify the appropriate dose and combination of BMS-986504 with other anticancer treatments that demonstrate a favorable benefit-risk profile in patients with homozygous MTAP deletion, in order to support its further clinical development.

Last update: 06/10/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe